January 1, 1989Thrombosis and Haemostasis

Pharmacokinetics and Haemostatic Status During Consecutive Infusions of Recom binant Tissue-Type Plasminogen Activator in Patients with Acute Myocardial Infarction

View Full Paper

Ask AI

Bookmark

Population

12 patients with acute myocardial infarction

Design

Case_series

Follow-up

90 minutes

Authors

ESErhard SeifriedGerman Red Cross PTP. TanswellBoehringer Ingelheim (Germany)DED. EllbrückFundación Juan March

Discussion

Member takes

Implication

Short rt-PA half-life and low variability may enable controlled AMI therapy; case report leaves open prospective validation.

Structured PICO

Population

12 patients with acute myocardial infarction

Intervention

Recombinant tissue-type plasminogen activator (rt-PA) consecutive intravenous infusion (10 mg in 2 minutes, followed by 50 mg in 1 hour and 30 mg in 1.5 hours) plus intravenous heparin

Outcome

Pharmacokinetics (peak plasma concentration, steady state levels, clearance, half-life) and systemic haemostatic effectssurrogate

Consecutive infusions of rt-PA in acute myocardial infarction patients show low interpatient pharmacokinetic variability and a short mean residence time, allowing precise control of therapy with moderate systemic haemostatic effects.

Cite This Study

Seifried et al. (1989) studied this question.

synapsesocial.com/papers/6a892d25ab71709247a2b96c https://doi.org/10.1055/s-0038-1646622

View Full Paper

Ask AI

Bookmark

Pharmacokinetics and Haemostatic Status During Consecutive Infusions of Recom binant Tissue-Type Plasminogen Activator in Patients with Acute Myocardial Infarction

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Pharmacokinetics and Haemostatic Status During Consecutive Infusions of Recom binant Tissue-Type Plasminogen Activator in Patients with Acute Myocardial Infarction

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider